P erioperative hypothermia is associated with increased postoperative morbidity. 1 Warming IV-administered fluids and blood products with an approved bloodwarming device is routinely performed to help maintain normothermia during surgery. The current guidelines from the AABB (formerly known as the American Association of Blood Banks) recommend against the mechanical warming of platelets (PLTs), 2 although there are no data to support this recommendation in the literature. 3 The main reason for this prohibition is derived from the contraindication listed in the operator's manual for the Level 1 fluid warmer, which follows from the manufacturer's decision not to perform the testing required by the Food and Drug Administration to license their product as suitable for PLT warming. a Given that the current practice of many anesthesiologists is to warm PLTs despite the AABB's recommendation, the goal of this study was to determine whether warming PLTs in a routinely used blood warmer had any effect on their function.
METHODS
This protocol was approved by the Total Quality Council, a division of the IRB of the University of Pittsburgh. Ten units of 3-day-old, PLT-rich plasma-derived whole blood PLTs were acquired from the Central Blood Bank (Pittsburgh, PA). Fivemilliliter aliquots were taken from each unit before warming and served as the control samples. The temperature of the units was measured immediately before warming. The units were then individually drained into a blood-warming device (Ranger Blood/Fluid Warming System, Arizant Healthcare Inc, Eden Prairie, MN) and held in the disposable for 2 minutes. Since the volume of each PLT unit was approximately 50 mL, the warming disposable had to be altered to accommodate the small volume. This was accomplished by removing all of the extraneous tubing as well as the air trap. This particular warming device will warm fluid up to 42ºC and is Food and Drug Administration-approved for warming packed red blood cell units and plasma. Postwarming samples were collected when the PLTs emerged from the effluent end of the warming device (warmed samples) and their temperature measured.
PLT aggregometry (PAP-4, Bio/Data Corporation, Horsham, PA) with 3 different agonists was performed on both the control and the warmed samples: adenosine diphosphate at 20, 10, and 5 μM concentrations; collagen at 1.9 mg/mL; and arachidonic acid at 5 mg/mL. The maximum amplitude of the clot was measured using BACKGROUND: Warming of IV-administered fluids and blood products is routinely performed in the operating room to help maintain normothermia. Current guidelines recommend against the warming of platelets (PLTs), although there is no evidence for this prohibition in the literature. Our goal in this pilot study was to determine whether the warming of stored PLTs had any effect on their function. METHODS: Ten units of 3-day-old, PLT-rich plasma-derived whole blood PLTs were acquired from the transfusion service. A 5-mL aliquot was taken from each unit before warming (control samples). The remainder of the unit was then passed into a blood-warming device and held there for 2 minutes. Postwarming (warmed) PLT samples were then collected from the effluent end of the warming device. PLT aggregometry assays with adenosine diphosphate, collagen, and arachidonic acid as agonists were performed on the control and warmed samples. Thromboelastography tests were also performed on the control and warmed samples from 6 of the 10 PLT units.
RESULTS:
The mean temperature of the control and warmed samples was 22.4°C ± 0.5°C and 37.8°C ± 2.3°C, respectively. There was no significant difference (all P ≥ 0.13) in any of the PLT aggregometry assays or in the maximum amplitude of the thromboelastography test between the control and the warmed samples. The observed mean of only 1 parameter decreased (PLT aggregometry with 5 μM adenosine diphosphate) by 5% (95% confidence interval, −115% to 105%). The maximum change observed was PLT aggregometry with arachidonic acid as agonist, which increased by 116% (95% confidence interval, −91% to 323%). CONCLUSION: Although small in size, the results of this study do not support the prohibition against mechanical PLT warming. Studies of PLT activation after warming are also warranted. (Anesth Analg 2013;117:575-8)
aNeStheSia & aNalgeSia
Stored Platelet Functionality Is Not Decreased After Warming thromboelastography (TEG®) on 6 of the 10 PLT units using kaolin as an activator in a Thrombelastograph® Hemostasis Analyzer (Model 5000, Haemonetics, Braintree, MA).
A study size of 10 PLT units was selected as pilot data to determine the normality of the data and standard deviations of the measurements. A power analysis was performed, showing that at least 300 units of PLTs would have to be tested to achieve 80% power to detect the small differences in the observed means. It was decided to report that the data from the 10 units, and not divert an additional 300 units of PLTs, a scarce resource, away from patient care. The results of the control and warmed samples were compared with an unpaired 2-tailed t test after all of the data distributions were shown to be normal using the Shapiro-Wilk test. 4 A P-value <0.01 was considered statistically significant. All statistical analysis was performed using GraphPad Prism software (Version 5.04, GraphPad Software Inc., San Diego, CA).
RESULTS
The mean temperature of the 10 control and the warmed samples was 22.4°C ± 0.5°C and 37.8°C ± 2.3°C, respectively. Results of aggregometry and TEG® tests are shown in Table 1 and Figure 1 . There was no significant difference (P ≥ 0.13) between the control and warmed samples in any of the PLT aggregometry tests or in the TEG® maximum amplitude measurement. The observed mean of only 1 parameter decreased (PLT aggregometry with 5 μM adenosine diphosphate) by 5% (95% confidence interval [CI], −115% to 105%). The maximum change observed was PLT aggregometry with arachidonic acid as agonist, which increased by 116% (95% CI, −91% to 323%).
DISCUSSION
In our study, a maximum decrease of 5% (95% CI, −115% to 105%) was seen in PLT function as measured by PLT aggregometry and TEG® between the unwarmed control and the warmed samples, although the intertest variability was quite large for both the unwarmed and warmed PLTs. PLT aggregation becomes abnormal during storage, 5, 6 and our results suggest that warming the PLTs with this device does not cause further degradation in their function. However, a larger sample size would be required to definitively establish whether warming induced further degradation of PLT function. Also, as activated PLTs contribute to the pathogenesis of transfusion-related acute lung injury, [7] [8] [9] [10] perhaps through the formation of neutrophil extracellular traps, 11 studying the impact of transit time through the warmer, flow rate, and temperature on the activation status of the warmed PLTs will also be important in determining their safety.
Some previous clinical studies that compared posttransfusion PLT counts demonstrated higher PLT counts (corrected for the dose of transfused PLTs and the patient's body surface area) after transfusion of warmed PLTs, [12] [13] [14] while others showed no difference in counts. 15, 16 The suggested mechanism for the improvement is that the spherical shape that the PLTs tend to adopt during routine storage at room temperature is reversed on warming, thereby facilitating longer in vivo survival and higher counts. 17, 18 Warming of PLTs before transfusion in the operating room will help to reduce the risk of hypothermia in the recipient. Typically, transfusing 4 to 5 PLT units has a volume of approximately 250 to 300 mL, which is similar to the volume of a single donor (apheresis) PLT unit. This volume is also approximately the same as that of a unit of red blood cells or 5% to 6% of the circulating blood volume of the average patient. Hence, by mass and temperature balance, assuming a total circulating blood volume of 5 L and assuming the specific heat of PLT units are the same as circulating blood, transfusing a 5-unit whole blood PLT dose that is stored at 22°C into a patient with a core body temperature of 37°C would decrease the temperature of the circulating blood volume by almost a full degree to 36.1°C.
A limitation of our study is the small sample size. However, after analysis of the data from the first 10 PLT units, and the lack of a clear difference in any of the measured variables, the decision was made to terminate the study so as not to divert more PLT units away from patient care. It is also possible that warming the PLTs caused damage to the PLTs in a way that was not measured in our tests; however, PLT aggregometry is the "gold standard" for PLT function measurement, and no difference between the control and warmed samples was observed. Our in vitro findings, as well as those from future in vitro studies as outlined earlier, can help inform the design of a clinical trial whereby the safety and efficacy of warmed PLTs are evaluated in patients undergoing surgery.
The purpose of this study was to analyze the effect of warming on PLT function. As no significant decrease was observed in any of the measured variables after warming in this small study, we suggest that the current practice Data are reported as mean ± SD and difference between means ± SD (99% confidence intervals [CIs]). P values are for unpaired 2-tailed t test. The maximum change in observed means was a 116% increase in platelet aggregometry with arachidonic acid as agonist (95% CI, −91% to 323%). The only observed decrease was platelet aggregometry with 5 µM adenosine diphosphate (ADP) as agonist, the mean of which decreased by 5% (95% CI, −115% to 105%). MA = maximum amplitude; TEG® = thromboelastography.
of warming the PLTs before infusion to an intraoperative patient is safe, although studies on PLT activation after warming are needed. E Figure 1 . Platetelet aggregometry and thromboelastography maximum amplitude (MA) results for the platelet units. ADP = adenosine diphosphate.
